GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.95 CNY | -4.59% |
|
-6.62% | -51.29% |
| Sales 2024 * | 5.43B 750M | Sales 2025 * | 6.48B 893M | Capitalization | 5.43B 749M |
|---|---|---|---|---|---|
| Net income 2024 * | 460M 63.47M | Net income 2025 * | 692M 95.48M | EV / Sales 2024 * | 1 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.84 x |
| P/E ratio 2024 * |
12
x | P/E ratio 2025 * |
8.06
x | Employees | 6,582 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.64% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.59% | ||
| 1 week | -6.62% | ||
| Current month | -38.85% | ||
| 1 month | -38.09% | ||
| 3 months | -48.30% | ||
| 6 months | -53.14% | ||
| Current year | -51.29% |
1 week
3.93
4.37
1 month
3.936.14
Current year
3.938.35
1 year
3.939.22
3 years
3.9311.97
5 years
3.9311.97
10 years
3.9337.66
| Managers | Title | Age | Since |
|---|---|---|---|
Min Niu
CEO | Chief Executive Officer | 54 | 07-12-24 |
Hong Xing Li
DFI | Director of Finance/CFO | 39 | 20-12-28 |
Pei Chen
BRD | Director/Board Member | 40 | 14-01-26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Jiang
CHM | Chairman | 63 | 07-12-24 |
Yong Jiang
BRD | Director/Board Member | 56 | 07-12-24 |
Min Niu
CEO | Chief Executive Officer | 54 | 07-12-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +7.39% | - | |
| 0.00% | 34 M€ | +4.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 3.95 | -4.59% | 60,703,670 |
| 24-05-27 | 4.14 | -3.04% | 39,212,510 |
| 24-05-24 | 4.27 | +0.95% | 49,710,250 |
| 24-05-23 | 4.23 | +2.92% | 66,802,230 |
| 24-05-22 | 4.11 | -2.84% | 77,377,370 |
End-of-day quote Shenzhen S.E., May 27, 2024
More quotes
GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of Chinese patent medicines. The Company is also engaged in the provision of Chinese medicine materials. The Company is also engaged in the distribution of fertilizers and purified water, and the operation of medical institutions. The Company conducts its businesses mainly within domestic markets.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.95
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -51.29% | 785M | |
| +42.07% | 6.28B | |
| -21.20% | 4.25B | |
| +5.38% | 3.36B | |
| -16.98% | 2.96B | |
| -5.82% | 2.45B | |
| +45.47% | 1.97B | |
| -12.67% | 1.61B | |
| -3.91% | 1.6B | |
| +44.56% | 1.51B |
- Stock Market
- Equities
- 002424 Stock
